Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/42042 
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoscheck, Ralfen
dc.date.accessioned2010-12-01T09:41:31Z-
dc.date.available2010-12-01T09:41:31Z-
dc.date.issued2008-
dc.identifier.citation|aIntereconomics|c0020-5346|v43|h5|nSpringer|lHeidelberg|y2008|p277-281en
dc.identifier.pidoi:10.1007/s10272-008-0261-zen
dc.identifier.urihttp://hdl.handle.net/10419/42042-
dc.language.isoengen
dc.publisher|aSpringer |cHeidelbergen
dc.subject.ddc330en
dc.subject.stwArzneimittelrechten
dc.subject.stwVerbraucherschutzen
dc.subject.stwPharmazeutisches Produkten
dc.subject.stwDeregulierungen
dc.subject.stwGesundheitswesenen
dc.subject.stwUSAen
dc.subject.stwDeutschlanden
dc.titleOff-label drugs vs. the merits of centralised regulatory control-
dc.type|aArticleen
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen
dc.identifier.printppn582112257en
econstor.documentversionPublished Versionen
econstor.citation.journaltitleIntereconomicsen
econstor.citation.issn0020-5346en
econstor.citation.volume43en
econstor.citation.issue5en
econstor.citation.publisherSpringeren
econstor.citation.publisherplaceHeidelbergen
econstor.citation.year2008en
econstor.citation.startpage277en
econstor.citation.endpage281en

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.